US Stock MarketDetailed Quotes

VTYX Ventyx Biosciences

Watchlist
  • 2.280
  • -0.160-6.56%
Close Dec 13 16:00 ET
  • 2.220
  • -0.060-2.63%
Post 19:57 ET
161.22MMarket Cap-0.97P/E (TTM)

About Ventyx Biosciences Company

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Company Profile

SymbolVTYX
Company NameVentyx Biosciences
Listing DateOct 21, 2021
Issue Price16.00
Founded2018
CEODr. Raju S. Mohan, PhD
MarketNASDAQ
Employees80
Fiscal Year Ends12-31
Address12790 El Camino Real,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-760-593-4832
Websitehttp://www.ventyxbio.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Raju S. Mohan, PhD
  • Director, Chief Executive Officer and President
  • 9.41M
  • Matthew Richard Moore
  • Chief Operating Officer
  • --
  • Dr. John M. Nuss, PhD
  • Chief Scientific Officer
  • 3.89M
  • Dr. Sheila Gujrathi, M.D.
  • Executive Chairman of the Board
  • 486.29K
  • Dr. Allison J. Hulme, PhD
  • Director
  • 834.42K
  • Onaiza Cadoret-Manier
  • Independent Director
  • 837.34K
  • Somasundaram Subramaniam, M.B.A.
  • Independent Director
  • 417.35K
  • William R. White, J.D.
  • Independent Director
  • 416.29K
  • Roy M. Gonzales
  • Interim Principal Financial Officer and Interim Principal Accounting Officer
  • --
Heat List
US
Overall
Symbol
Price
% Chg

No Data